Antimicrobial resistance is one of the major problems in current practical medicine. The
spread of genes coding for resistance determinants among bacteria challenges the use of …

Various boron-containing drugs have been approved for clinical use over the past two
decades, and more are currently in clinical trials. The increasing interest in boron-containing …

Since the seminal work of Zhang in 2016, donor–acceptor cyanoarene-based fluorophores,
such as 1, 2, 3, 5-tetrakis (carbazol-9-yl)-4, 6-dicyanobenzene (4CzIPN), have been widely …

β-Lactam antibiotics are the most widely prescribed antibacterial drugs due to their low
toxicity and broad spectrum. Their action is counteracted by different resistance mechanisms …

Boron-containing compounds (BCC) have emerged as important pharmacophores. To date,
five BCC drugs (including boronic acids and boroles) have been approved by the FDA for …

Structures of several dozen of known antibacterial, antifungal or antiprotozoal agents are
based on the amino acid scaffold. In most of them, the amino acid skeleton is of a crucial …

Serine/metallo-carbapenemase-coproducing pathogens, often referred to as “superbugs”,
are a significant clinical problem. They hydrolyze nearly all available β-lactam antibiotics …

Resistance to β‐lactam antibacterials is commonly associated with the production of the
serine β‐lactamases (SBLs) and/or metallo‐β‐lactamases (MBLs). Although clinically useful …

The effectiveness of β-lactam antibiotics is increasingly influenced by serine β-lactamases
(SBLs) and metallo-β-lactamases (MBLs), which can hydrolyze β-lactam antibiotics. The …

Antimicrobial stewardship is imperative when treating bacterial infections because the
misuse and overuse of antibiotics have caused pathogens to develop life-threatening …